United Therapeutics Corp
UTHR
Market Cap$11.8B
Close$
$376.68
42.5% upside
Current Fair Value
42.5% upsideUndervalued by 42.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.80 Billion |
|---|---|
| Enterprise Value | $9.69 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $21.13 |
| Beta | 0.32 |
| Outstanding Shares | 44,355,694 |
| Avg 30 Day Volume | 580,865 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.23 |
|---|---|
| PEG | 41.19 |
| Price to Sales | 4.72 |
| Price to Book Ratio | 2.2 |
| Enterprise Value to Revenue | 3.88 |
| Enterprise Value to EBIT | 7.71 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...